JO

Jude Onyia

Chief Scientific Officer at Neurocrine Biosciences

Jude Onyia, Ph.D., was appointed Chief Scientific Officer in November 2021 and leads the drug discovery and non-clinical development teams responsible for bolstering and advancing the company’s pipeline of therapeutic candidates. A scientist with more than 25 years of experience in the pharmaceutical industry, Dr. Onyia is the former Vice President of Biotechnology Discovery Research at Eli Lilly & Co. At Lilly, Dr. Onyia contributed to the discovery and/or advancement of more than 60 clinical candidates across multiple therapeutic areas, which led to seven approved medicines. He also was responsible for more than 50 pre-candidate programs across multiple therapeutic areas. Dr. Onyia holds a B.S. in Forest Biology from the State University of New York, as well as a Ph.D. in Cell and Molecular Biology from the SUNY Health Science Center at Syracuse.

Links

Timeline

  • Chief Scientific Officer

    November, 2021 - present

View in org chart